PCAMBRO Stock Latest News
Private CompaniesAmbros Therapeutics Highlights Neridronate Development for CRPS-11w agoAMBRO
Private CompaniesAmbros Therapeutics Advances Phase 3 Trial of Neridronate for CRPS2w agoAMBRO
Private CompaniesAmbros Therapeutics Strengthens Board to Support Pivotal CRPS Phase 3 Program2M agoAMBRO
Private CompaniesAmbros Therapeutics Plans Merger With Werewolf Therapeutics and $150 Million Financing2M agoAMBRO
Private CompaniesAmbros Therapeutics Highlights Regulatory Progress and Clinical Data for Neridronate4M agoAMBRO
Private CompaniesAmbros Therapeutics Highlights Pivotal CRPS-1 Program and Community Engagement5M agoAMBRO
Private CompaniesAmbros Therapeutics Advances Neridronate Into Pivotal Phase 3 CRPS Trial5M agoAMBRO
Private CompaniesAmbros Therapeutics Reaches First-Patient Dosing in Pivotal Phase 3 CRPS Trial5M agoAMBRO
Private CompaniesAmbros Therapeutics – Weekly Recap5M agoAMBRO
Private CompaniesAmbros Therapeutics Highlights CRPS Advocacy Role and Phase 3 Trial Focus5M agoAMBROPrivate CompaniesAmbros Therapeutics Highlights Support for CRPS Community and Phase 3 Trial Progress5M agoAMBRO
Private CompaniesPhase 3 CRPS Trial Spotlight Positions Ambros Therapeutics in High-Need Pain Market6M agoAMBRO
Private CompaniesAmbros Therapeutics’ Pivotal CRPS-1 Trial Highlighted in Rare-Disease Newsletter6M agoAMBRO
Private CompaniesAmbros Therapeutics Expands Quality Leadership Ahead of NDA and Commercial Milestones7M agoAMBROPrivate CompaniesAmbros Therapeutics Gains U.S. Patent Allowance Supporting Neridronate Exclusivity7M agoAMBRO
Private CompaniesAmbros Therapeutics Gains Patent Allowance Supporting Potential Neridronate Exclusivity7M agoAMBRO





